Objective To investigate the impact of concordance between clinical stage and pathological stage of colorectal cancer on prognosis and survival, and evaluate its prognostic value across different populations. Methods Based on 20,455 patients from the SEER database, we analyzed the association between staging consistency, survival, and clinical characteristics. A multivariate competing risks model and ROC analysis were used to evaluate prognostic performance. Results Staging was consistent in 86.9% of patients; 12.1% had pathological downstaging and 1.0% had upstaging. Among the three groups, the group with consistent clinical and pathological staging had the highest survival rate. There were statistically significant differences among the three groups in tumor biological characteristics and treatment-related factors such as peripheral nerve invasion, tumor deposition, anatomical location, and time from diagnosis to treatment (all P<0.05). In the overall cohort, clinical overstaging was associated with worse prognosis in unadjusted models but showed no significant effect after full adjustment. Among pathological stage III patients, those clinically overstaged had better outcomes (P<0.05). In patients aged 20~45, clinical overstaging was linked to worse prognosis (HR=1.91, P=0.045). For patients under 45, clinical staging had slightly higher sensitivity (89.4% vs 86.4%) but lower specificity (79.6% vs 82.9%) compared to pathological staging, with similar discriminatory ability (AUC: 0.894 vs 0.891). Conclusion Staging consistency in colorectal cancer is high, but discordance significantly affects prognosis. Clinical overstaging warrants extended follow-up or closer postoperative monitoring; pathological overstaging suggests the need for adjuvant therapy. In patients aged 20~45, treatment intensity should be guided by clinical stage, even with lower pathological stage